secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001108205-23-000073
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q3 net loss $12.2M ($2.13/sh); cash $68.5M; emavusertib studies resume
----------------------------------------------------------------------------

- Net loss narrowed to $12.2M from $13.3M YoY; revenue unchanged at $2.8M from Erivedge royalties.
- Cash, cash equivalents and investments total $68.5M; company expects funding into 2025.
- Patient enrollment restarted in Phase 1/2 TakeAim Leukemia and Lymphoma emavusertib studies after partial clinical hold lift.
- Plans to initiate triplet combo study of emavusertib with azacitidine and venetoclax in AML in Q4 2023.
- Updated TakeAim Lymphoma data expected at ASH December 2023; leukemia data in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820523000073/0001108205-23-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820523000073/cris-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001108205-23-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer